Weightloss – Neuroscience

Mayo Clinic employee health insurance will cap coverage of weight-loss drugs

November 11, 2023 by Wilma

ROCHESTER Mayo Clinic employees insured by the Mayo Medical Plan will see a new lifetime limit on weight-loss drug coverage starting in 2024. In a letter provided to the Post Bulletin, those prescribed FDA-approved weight loss medications, including Wegovy, Saxenda, Contrave and others, will have the cost of those drugs… Continue Reading Mayo Clinic employee health insurance will cap coverage of weight-loss drugs

There’s a new entry into the weight-loss drug boom. Here’s the stock’s outlook

November 9, 2023 by Wilma

AstraZeneca is the latest player to enter the weight-loss drug space, a market that some analysts say could reach $100 billion by 2030. On Thursday, the biopharmaceutical company announced it had entered into a licensing agreement with Eccogene for ECC5004 , an oral glucagon-like peptide 1 receptor agonist. This drug,… Continue Reading There’s a new entry into the weight-loss drug boom. Here’s the stock’s outlook

Senator launches new models to manage costs of weight-loss drugs like Ozempic

November 9, 2023 by Wilma

WASHINGTON With blockbuster sales of Novo Nordisks Wegovy and Ozempic and the approval of a new rival this week, everyone in Washington is thinking about how to deal with the surging tide of weight-loss drug costs. Explosive national demand for weight management therapies and diabetes drugs like Ozempic, all of… Continue Reading Senator launches new models to manage costs of weight-loss drugs like Ozempic

Wall Street is wondering what impact weight-loss drugs will have on consumer giants, but it may be too early to tell.

November 6, 2023 by Wilma

Delta Air Lines, Pepsi, Philip Morris International and Darden Restaurants are among companies facing questions about the impact of GLP-1 on their bottom lines. In the United States, only a fraction of obese people currently take a GLP-1. That figure could rise to 13% by the end of the decade,… Continue Reading Wall Street is wondering what impact weight-loss drugs will have on consumer giants, but it may be too early to tell.

Demand for Ozempic and Wegovy increases illegal sales of weight-loss drugs

November 1, 2023 by Wilma

Business By Shannon Thaler Published November 1, 2023, 12:10 p.m. ET Growing demand for Ozempic and Wegovy, made by Novo Nordisk, has fueled a rise in illegal sales of weight-loss drugs in Denmark, where the pharmaceutical company is based, the Danish Medicines Agency reported. The agency said in a statement… Continue Reading Demand for Ozempic and Wegovy increases illegal sales of weight-loss drugs

Demand for Ozempic and Wegovy increases illegal sales of weight-loss drugs

November 1, 2023 by Wilma

Growing demand for Ozempic and Wegovy, made by Novo Nordisk, has fueled a rise in illegal sales of weight-loss drugs in Denmark, where the pharmaceutical company is based, the Danish Medicines Agency reported. The agency said in a statement released Tuesday that authorities are aware of 26 websites illegally selling… Continue Reading Demand for Ozempic and Wegovy increases illegal sales of weight-loss drugs

Weight-loss drugs are safe if used correctly, West Palm Beach doctor says

October 21, 2023 by Wilma

WEST PALM BEACH, Florida. The Journal of the American Medical Association reports that some of the most popular medications available for weight loss, including Ozempic, Wegovy, and Saxenda, may be linked to an increased risk of serious stomach problems in some people. The research was published earlier this month and… Continue Reading Weight-loss drugs are safe if used correctly, West Palm Beach doctor says